137 related articles for article (PubMed ID: 38206706)
41. Real-world Prescription Pattern, Discontinuation and Costs of Ibrutinib-Naïve Patients with Chronic Lymphocytic Leukemia: An Italian Healthcare Administrative Database Analysis.
Ronconi G; Dondi L; Calabria S; Piccinni C; Pedrini A; Esposito I; Martini N
Clin Drug Investig; 2021 Jul; 41(7):595-604. PubMed ID: 34032988
[TBL] [Abstract][Full Text] [Related]
42. MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia.
Saba NS; Wong DH; Tanios G; Iyer JR; Lobelle-Rich P; Dadashian EL; Liu D; Fontan L; Flemington EK; Nichols CM; Underbayev C; Safah H; Melnick A; Wiestner A; Herman SEM
Cancer Res; 2017 Dec; 77(24):7038-7048. PubMed ID: 28993409
[TBL] [Abstract][Full Text] [Related]
43. Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status.
Huang Q; Deering KL; Harshaw Q; Leslie LA
Adv Ther; 2022 Jul; 39(7):3292-3307. PubMed ID: 35608754
[TBL] [Abstract][Full Text] [Related]
44. [Tumors of lymphoid and hematopoietic tissue of spleen: a clinicopathologic analysis of 53 cases].
Chen DB; Shen DH; Zhang H; Wang Y; Song QJ; Yang SM; Fang XZ
Zhonghua Bing Li Xue Za Zhi; 2017 Nov; 46(11):775-781. PubMed ID: 29136691
[No Abstract] [Full Text] [Related]
45. In Human Visualization of Ibrutinib-Induced CLL Compartment Shift.
Mayerhoefer ME; Haug A; Jäger U; Pichler V; Pfaff S; Wester HJ; Hacker M; Kazianka L; Staber PB
Cancer Immunol Res; 2020 Aug; 8(8):984-989. PubMed ID: 32580942
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data.
Tombak A; Pepedil Tanrıkulu F; Durusoy SS; Dinçyürek HD; Kaya E; Ümit EG; Yavaşoğlu İ; Mehtap Ö; Deveci B; Özcan MA; Terzi H; Okay M; Sayınalp N; Yılmaz M; Okan V; Kızıklı A; Özcan Ö; Çetin G; Demircioğlu S; Aydoğdu İ; Saydam G; Davulcu EA; İlhan G; Uçar MA; Özet G; Akpınar S; Turgut B; Berber İ; Kurtoğlu E; Sönmez M; Batur DS; Yıldırım R; Özkocamaz V; Güneş AK; Sahip B; Ertop Ş; Akay OM; Baştürk A; Doğu MH; Akdeniz A; Ünal A; Seyhanlı A; Gürkan E; Çekdemir D; Ferhanoğlu B
Turk J Haematol; 2021 Dec; 38(4):273-285. PubMed ID: 34448556
[TBL] [Abstract][Full Text] [Related]
47. Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia.
Hou JZ; Ryan K; Du S; Fang B; Marks S; Page R; Peng E; Szymanski K; Winters S; Le H
Future Oncol; 2021 Dec; 17(35):4959-4969. PubMed ID: 34783255
[TBL] [Abstract][Full Text] [Related]
48. Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia.
Huang Q; Emond B; Lafeuille MH; Gupta D; Lefebvre P; Sundaram M; Mato A
Curr Med Res Opin; 2020 Dec; 36(12):2009-2018. PubMed ID: 33044848
[TBL] [Abstract][Full Text] [Related]
49. Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia.
Hampel PJ; Call TG; Rabe KG; Ding W; Muchtar E; Kenderian SS; Wang Y; Leis JF; Witzig TE; Koehler AB; Fonder AL; Schwager SM; Van Dyke DL; Braggio E; Slager SL; Kay NE; Parikh SA
Oncologist; 2020 Nov; 25(11):974-980. PubMed ID: 32886416
[TBL] [Abstract][Full Text] [Related]
50. Screening and monitoring of the BTK
Bödör C; Kotmayer L; László T; Takács F; Barna G; Kiss R; Sebestyén E; Nagy T; Hegyi LL; Mikala G; Fekete S; Farkas P; Balogh A; Masszi T; Demeter J; Weisinger J; Alizadeh H; Kajtár B; Kohl Z; Szász R; Gergely L; Gurbity Pálfi T; Sulák A; Kollár B; Egyed M; Plander M; Rejtő L; Szerafin L; Ilonczai P; Tamáska P; Pettendi P; Lévai D; Schneider T; Sebestyén A; Csermely P; Matolcsy A; Mátrai Z; Alpár D
Br J Haematol; 2021 Jul; 194(2):355-364. PubMed ID: 34019713
[TBL] [Abstract][Full Text] [Related]
51. Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Fraser GAM; Chanan-Khan A; Demirkan F; Santucci Silva R; Grosicki S; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Loscertales J; Avigdor A; Rule S; Samoilova O; Pavlovsky MA; Goy A; Mato A; Hallek M; Salman M; Tamegnon M; Sun S; Connor A; Nottage K; Schuier N; Balasubramanian S; Howes A; Cramer P
Leuk Lymphoma; 2020 Dec; 61(13):3188-3197. PubMed ID: 32762271
[TBL] [Abstract][Full Text] [Related]
52. Early Transformation to Classic Hodgkin Lymphoma in a Chemotherapy-naïve Chronic Lymphocytic Leukemia Patient upon Initial Treatment with Ibrutinib.
Koshiishi M; Odate T; Nakagawa Y; Suzuki J; Kumagai T; Kawashima I; Yamamoto T; Nakajima K; Tanaka M; Oishi N; Kondo T; Kirito K
Intern Med; 2021 Oct; 60(20):3305-3308. PubMed ID: 33896865
[TBL] [Abstract][Full Text] [Related]
53. An 81-Year-Old Man with a 6-Year History of Chronic Lymphocytic Leukemia Presenting with Disease Flare Following Ibrutinib Discontinuation.
Pozzi S; Potenza L; Giusti D; Colaci E; Pioli V; Leonardi G; Maccaferri M; Luppi M; Marasca R
Am J Case Rep; 2022 Aug; 23():e935941. PubMed ID: 36016481
[TBL] [Abstract][Full Text] [Related]
54. Ibrutinib skin toxicities: Report of two cases.
Bloomquist MS; Curry JL; Krishnan B; Rivero G; Curry CV; Diwan AH
J Cutan Pathol; 2022 Apr; 49(4):363-368. PubMed ID: 34726785
[TBL] [Abstract][Full Text] [Related]
55. Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia.
Solman IG; Blum LK; Burger JA; Kipps TJ; Dean JP; James DF; Mongan A
Leuk Res; 2021 Mar; 102():106520. PubMed ID: 33611131
[TBL] [Abstract][Full Text] [Related]
56. Real-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a Named Patient Program.
Mulligan SP; Opat S; Cheah CY; Kuss B; Hertzberg M; Marlton P; Poplar S; Puig A; McGeachie M; Weinkove R; Tam CS
Leuk Lymphoma; 2023 Feb; 64(2):312-318. PubMed ID: 36423351
[TBL] [Abstract][Full Text] [Related]
57. Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance.
Omi A; Nomura F; Tsujioka S; Fujino A; Akizuki R
J Clin Exp Hematop; 2022 Sep; 62(3):136-146. PubMed ID: 35831100
[TBL] [Abstract][Full Text] [Related]
58. IBRUTINIB FOR CONTROL OF CHOROIDAL AND ORBITAL METASTASIS FROM CHRONIC LYMPHOCYTIC LEUKEMIA.
Sieburth RM; Weaver CD; Kirzhner M; Shildkrot Y
Retin Cases Brief Rep; 2023 Mar; 17(2):120-122. PubMed ID: 33411467
[TBL] [Abstract][Full Text] [Related]
59. Non hemorrhagic pericardial effusion from ibrutinib İn a patient without comorbidities.
Aslan Candır B; Yiğenoğlu TN; Kızıl Çakar M; Dal MS; Altuntaş F
J Oncol Pharm Pract; 2022 Jun; 28(4):972-974. PubMed ID: 35006020
[TBL] [Abstract][Full Text] [Related]
60. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
Lee CS; Rattu MA; Kim SS
J Oncol Pharm Pract; 2016 Feb; 22(1):92-104. PubMed ID: 25425007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
